Medidur FAME enrolment passes half way mark

Article

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

FAME is a double-masked, randomized, multicentre study that will follow around 900 patients across the US, Canada, Europe and India for 36 months, studying the efficacy and safety of Medidur.

Medidur is an injectable intravitreal insert that is designed to deliver low doses of fluocinolone acetonide to the retina over a period of up to three years, as a treatment for diabetic macular oedema (DME). Using a proprietary 25-gauge transconjunctival injector system, Medidur is inserted into the vitreous during an outpatient procedure.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.